E-LIB Suche - Ergebnisse für: P. Buggisch

1

186P Patients' characteristics, outcomes, and costs of live..:

Schrodi, S. ; Becht, S. ; von Bergwelt, M....
Annals of Oncology. 35 (2024) - p. S84 , 2024

Link: https://doi.org/10.1016/..

2

195P Risk factors in patients with hepatocellular carcinoma..:

Becht, S. ; Berger-Thürmel, K. ; von Bergwelt, M....
Annals of Oncology. 35 (2024) - p. S87 , 2024

Link: https://doi.org/10.1016/..

3

Strategietreffen: Virushepatitis in Deutschland eliminieren..:

Tergast, T. L. ; Protzer, U. ; Zeuzem, S....
Zeitschrift für Gastroenterologie. 61 (2023) 2 - p. 198-201 , 2023

Link: https://doi.org/10.1055/..

4

Therapy with DAAs in patients with chronic hepatitis C and ..:

Wiegand, J. ; Buggisch, P. ; Mauss, S....
Journal of Hepatology. 68 (2018) - p. S256 , 2018

Link: https://doi.org/10.1016/..

5

Variables associated with persistence of elevated ALT after..:

Mauss, S. ; Buggisch, P. ; Boeker, K....
Journal of Hepatology. 68 (2018) - p. S302-S303 , 2018

Link: https://doi.org/10.1016/..

6

Disease progression is affected by pattern of serum alanine..:

Knop, V. ; Vermehren, J. ; Petersen, Jörg...
Journal of Hepatology. 68 (2018) - p. S496 , 2018

Link: https://doi.org/10.1016/..

7

Treatment efficacy and safety of seladelpar, a selective pe..:

Hirschfield, G. ; Boudes, P. ; Bowlus, C....
Journal of Hepatology. 68 (2018) - p. S105-S106 , 2018

Link: https://doi.org/10.1016/..

8

Changing landscape of HCV treatment in Germany: Data from a..:

Petersen, J. ; Olah, K. ; Lorenzen, T....
Journal of Hepatology. 68 (2018) - p. S261-S262 , 2018

Link: https://doi.org/10.1016/..

9

Scaling up HCV-DAA treatment in patients on opioid substitu..:

Christensen, S. ; Buggisch, P. ; Mauss, S....
Journal of Hepatology. 68 (2018) - p. S21-S22 , 2018

Link: https://doi.org/10.1016/..

10

Direct medical costs associated with the extrahepatic manif..:

Cacoub, P. ; Buggisch, P. ; Carrión, J. A....
Journal of Viral Hepatitis. 25 (2018) 7 - p. 811-817 , 2018

Link: https://doi.org/10.1111/..

11

Real-world effectiveness and safety of Ombitasvir, Paritapr..:

Teuber, G. ; Buggisch, P. ; Naumann, U....
Journal of Hepatology. 66 (2017) 1 - p. S530 , 2017

Link: https://doi.org/10.1016/..

12

Real-world effectiveness and cost per SVR of Sofosbuvir/Vel..:

Buggisch, P. ; Atanasov, P. ; Wursthorn, K...
Journal of Hepatology. 66 (2017) 1 - p. S730 , 2017

Link: https://doi.org/10.1016/..

13

Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF)..:

Buggisch, P. ; Moreno, A. ; Isakov, V....
Journal of Hepatology. 66 (2017) 1 - p. S729-S730 , 2017

Link: https://doi.org/10.1016/..

14

Resistance patterns in patients with chronic hepatitis C ge..:

Dietz, J. ; Vermehren, J. ; Susser, S....
Journal of Hepatology. 66 (2017) 1 - p. S525 , 2017

Link: https://doi.org/10.1016/..

15

Direct medical costs associated with the extrahepatic manif..:

Cacoub, P. ; Buggisch, P. ; Beckerman, R..
Journal of Hepatology. 66 (2017) 1 - p. S499 , 2017

Link: https://doi.org/10.1016/..